Saturday 17 October 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.58
0.32
−8.21%
Follow RZLT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
9.68 | 15.84 | 14.18 | 15.15 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.90 | 6.74 | 5.33 | 7.39 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.85 | 0.89 | 0.96 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.13) | (0.13) | (0.20) | (0.17) | |
Cash per Share |
1.04 | 1.16 | 1.28 | 1.47 | |
Shareholders Equity per Share |
0.97 | 1.12 | 1.23 | 1.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.12 | 1.23 | 1.42 | |
Free Cash Flow |
(13.15) | (13.73) | (20.32) | (17.43) | |
Working Capital |
99.09 | 114.35 | 125.58 | 144.50 | |
Net Current Asset Value |
98.35 | 113.42 | 124.48 | 143.21 | |
| Other line items | |||||
Quick Ratio |
9.44 | 15.61 | 13.95 | 14.91 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.13) | (0.13) | (0.20) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.42 | 4.85 | 3.47 | 2.72 | |
Average Assets |
144.17 | 110.10 | 125.32 | 141.04 | |
Average Common Equity |
131.41 | 99.70 | 113.79 | 130.30 |
Columns are period end dates · fundamentals updated 2 Oct 2026